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Summary In the last year, a number of studies have reported the expression of bcl-2 in colorectal adenocarcinomas. However, the influence
of bcl-2 expression on response to chemotherapy and outcome in patients with advanced colorectal adenocarcinoma has not been reported.
We analysed bcl-2 expression in 231 colorectal tumours from patients that were treated by surgery alone or with 5-fluorouracil-based
chemotherapy. Of 231 tumours, 149 (64.5%) overexpressed bcl-2. Bcl-2 expression was associated with low plasma CEiA levels (P=0.013)
and inversely associated with poor differentiation (P=0.049). However, bcl-2 expression did not significantly influence failure-free or overall
survival in surgically treated patients. In the group of patients receiving 5-fluorouracil-based chemotherapy bcl-2 expression did not influence
response to chemotherapy; nor did it effect failure-free or overall survival.
Key words: bcl-2; chemotherapy; 5-fluorouracil; colorectal cancer
The bcl-2 oncogene was originally identified through its associa-
tion with the t(14;18) chromosomal translocation common in low-
grade lymphomas (Bakhshi et al, 1985). The precise biochemical
function of bcl-2 remains unknown, although sequence compar-
ison, and in vitro and in vivo studies have shown thatitbelongs to a
family ofproteins that regulate programmed cell death (apoptosis)
(Vaux et al, 1988; McDonnell et al, 1992; Boise et al, 1995). In
vitro studies have also demonstrated thatexpression ofbcl-2 results
in the acquisition of resistance to a variety of agents that induce
apoptosis (Miyashita and Reed, 1992; Fisher et al, 1993; Walton
et al, 1993). Bcl-2 is expressed widely during embryogenesis and
also in a number of normal adult tissues, including stem cells,
peripheral neurones and some lymphoid cells (Hockenberry et al,
1991). The protein is mainly localized to mitochondrial and nuclear
membranes and to the endoplasmic reticulum (Akao et al, 1994).
Bcl-2 expression has been detected in a number of tumours
including breast (Bhargava et al, 1994; Joensuu et al, 1994;
Hellemans et al, 1995; Sierra et al, 1995; Leek et al, 1995), colon
(Hague et al, 1994; Bosari et al, 1995; Ofner et al, 1995; Sinicrope
et al, 1995a,b; Baretton et al, 1996; Watson et al, 1996), gastric
(Lauwers et al, 1995), lung (Pezzella et al, 1993; Ben Ezra et al,
1994), lymphoma (Hermine et al, 1996; Hill et al, 1996), ovary
(Kuwashima et al, 1994) and prostate (McDonnell et al, 1992;
Colombel et al, 1993). We and others have recently shown that
bcl-2 expression in patients with diffuse large-cell lymphomas is
associated with an increased rate of relapse and a significantly
worse prognosis (Hermine et al, 1996; Hill et al, 1996). In
contrast, there are some reports in breast tumours that suggest
that tumours expressing bcl-2 have a better prognosis and are
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more responsive to endocrine therapy (Gee et al, 1994; Hellemans
et al, 1995; Hurlimann et al, 1995).
A number of studies have examined the association of bcl-2
expression with avariety ofhistopathological andclinicalparameters
in colorectal adenocarcinoma (Bosari et al, 1995; Ofneret al, 1995;
Table 1 Patient characteristics and bcl-2 expression
bel-2 positive bcl-2 negative P-value
(%) (%)
Sex
M 83 (58) 47 (57)
F 66 (44) 35 (43) 0.813
Performance status
0 19 (13) 7 (9)
1 40 (27) 20 (24)
2 30 (20) 10 (12)
3 5 (3) 4 (5)
Unknown 55 (37) 41 (50) 0.251
Dukes' staging
A 50 (34) 37 (45)
B 28 (19) 8 (10)
C 31 (21) 18 (22)
D 39 (26) 19 (23)
Missing 1 (1) 0 (0) 0.181
Differentiation
Well/moderate 139 (93) 70 (85)
Poor 10 (7) 12 (15) 0.049
Tumour site
Right hemicolon 26 (17) 14 (17)
Transverse colon 9 (6) 3 (4)
Left hemicolon 8 (5) 6 (7)
Sigmoid colon/rectum 100 (67) 54 (66)
Unknown 6 (4) 5 (6) 0.845
CEA
>5 ng ml-' 67 (45) 34 (41)
<5ngml-' 19(13) 2(2)
Unknown 63 (42) 46 (56) 0.013
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Figure 1 Bcl-2 staining of normal colorectal tissue and colorectal tumours.
(A) Normal colorectal tissue showing staining of the crypts and adjacent
lymphocytes (original magnification x 200). (B) Bcl-2-negative colorectal
carcinoma with staining of internal positive control lymphocytes (original
magnification x 200). (C) Bcl-2-positive tubulovillous colorectal carcinoma
(original magnification x 200)
Sinicrope et al, 1995a,b; Baretton et al, 1996). Three studies
concluded that bcl-2 expression was associated with increased
survival (Ofner et al, 1995; Sinicrope et al, 1995; Baretton et al,
1996), an observation similar to that seen in breast tumours.
However, a larger study could not detect any association between
survival and bcl-2 expression (Bosari et al, 1995). None of these
studies have examined the influence of bcl-2 expression on
response to chemotherapy. In three of these studies the patients
were treated by surgery alone (Ofner et al, 1995; Sinicrope et al,
1995; Baretton et al, 1996) and in the fourth study there was
no prior chemotherapy (Bosari et al, 1995), whereas treatment
following surgery was not reported.
A drug often used in the adjuvant and palliative treatment of
colorectal tumours is 5-fluorouracil (Cunningham and Findlay,
1993; Moertel, 1994). This agent inhibits nucleic acid biosynthesis
by a number of different mechanisms and induces apoptosis both
in vitro and in vivo (Ijiri and Potten, 1983; Fisher et al, 1993). In
vitro studies have demonstrated that bcl-2 can inhibit apoptosis
induced by 5-fluorouracil (Fisher et al, 1993). Therefore, we were
interested in the influence of bcl-2 on response to 5-fluorouracil-
based chemotherapeutic regimens in patients with colorectal
tumours. The first aim ofthis study was to investigate the associa-
tion between bcl-2 expression and outcome in colorectal cancer.
The second aim was to examine whether response and outcome
following chemotherapy were altered in those patients who
expressed bcl-2.
MATERIALS AND METHODS
Patients
Slides were cut from paraffin-embedded tissue resected from
patients with colorectal tumours at time of diagnosis. We were
able to identify archive material from 231 patients, whose details
are summarized in Table 1. Patients had either been treated by
surgery, with a combination of surgery and chemotherapy or with
chemotherapy alone. A total of 96 patients had Dukes' A and B
colorectal tumours at diagnosis that were considered not to require
adjuvant chemotherapy. They were treated by surgical resection
alone. A total of 135 patients had advanced or metastatic disease.
They had received no prior chemotherapy or radiotherapy and
were enrolled in two randomized clinical trials at the Royal
Marsden Hospital (Hill et al, 1995a,b). These patients received
either bolus or protracted venous infusional 5-fluorouracil ± inter-
feron. The criteria for inclusion in these studies, for response and
for follow-up are detailed elsewhere (Hill et al, 1995a,b).
Bc1-2 immunohistochemistry
Sections (3 jim) were deparaffinized in Histoclear and rehydrated
in 100% ethanol. Endogenous peroxidase activity was quenched
with 20% acetic acid. Slides were immersed in citrate buffer solu-
tion pH 6.0 and were microwaved for 10 min in a 850-W
microwave (Cattoretti et al, 1993). The samples were cooled for 20
min and rinsed in tris-buffered saline. Slides were blocked with 5%
horse serum in phosphate-buffered saline (PBS) for 20 min and
incubated in a humidified chamber for 90 min at room temperature
with abcl-2 antibody (2.5 ,ig ml-' ofmonoclonal antibody no. 100,
Oncogene Science) diluted in PBS/0.5% bovine serum albumin.
Bcl-2-antibody complexes were detected using an APAAP system
(Vector Laboratories) following the manufacturer's instructions.
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Slides were counterstained with haematoxylin and mounted in
glycerine gelatine. A lymph node section was included as a posi-
tive control with each batch of slides. The distribution of bcl-2
expression in normal colonic tissue provided additional internal
positive and negative controls.
Evaluation of slides stained for bcl-2
Slides were evaluated by a pathologist, who was unaware of the
clinical details of these patients, using the system described by
Sinicrope et al. (1995b). This scores both for surface area stained
and also for intensity of staining. Infiltrating lymphocytes,
ganglion cells and peripheral nerve trunks all stained strongly for
bcl-2 and provided an internal control for intense staining.
Tumours were only scored negative for bcl-2 expression if the
internal positive controls retained their normal staining pattern.
Slides were also reviewed for confirmation of pathological stage
and grade.
Statistical analysis
For statistical analysis we evaluated tumours that stained either
bcl-2 positive (>5% of tumour cells staining) or were negative for
bcl-2 staining. The 5% cut-off was as described by Sincirope et al.
(1995b); grading the bcl-2 expression between weak and high
staining did not influence the results described below (data not
shown). Statistical differences between the variables were
compared using chi-square analysis with Fisher's exact test when
necessary. When a significant imbalance was demonstrated using
the chi-square test, survival data were stratified by this factorusing
the Mantel-Haenszel test. Failure-free survival (time to progres-
sion or death) and overall survival were examined using the
Table 2 Bcl-2 expression and relapse or response to chemotherapy
bcl-2 positive bcl-2 negative P-value
(%) (%)
Surgical group
No evidence of relapse 47 (85) 34 (83)
definite relapse 6 (11) 7 (17)
Lost to followup 2 (4) 0 (0) 0.150
Chemotherapy group
Complete response 3 (3) 2 (5)
Partial response 20 (21) 8 (20)
No response 46 (49) 17 (41)
Progressive disease 23 (24) 14 (34)
Missing 2 (2) 0 (0) 0.438
Table 3 Factors influencing response or overall survival in the chemotherapy
group
Response Survival
(P-value) (P-value)
Dukes' stage stage at diagnosis (A, B, C vs D)0.049 0.760
Age (<61 years vs >61 years) 0.150 0.332
Differentiation (well vs poor/moderate) 0.080 0.164
Plasma CEA (<5 ng ml-' vs >5 ng ml-') 0.570 0.002
Performance status (0,1 vs 2,3) 0.950 0.017
bcl-2 (positive vs negative) 0.211 0.150
Kaplan-Meier product-limit method. Differences between survival
curves were examined using the log-rank test.
RESULTS
Immunostaining for bcl-2 protein
Discrete, slightly granular staining was identified in the crypts of
normal colonic epithelium, basal keratinocytes, lymphocyte
ganglion cells and to a lesser extent smooth muscle of vessels
(Figure 1A). In addition to cytoplasmic staining, some perinuclear
staining was occasionally observed. The cellular and subcellular
staining pattern was consistent with the known distribution and
subcellularlocalization ofbcl-2 (Hague et al, 1994; Sinicrope et al,
1995b). The tumours and adjacent dysplastic epithelia, when
present, showed patchy staining that was not obviously localized
to surface, periphery or centre of the tumours. Although tumour
staining was heterogeneous, lymphocyte staining remained
constant across the section. In all cases, wlien present, normal
colonic tissue retained the normal staining pattern forbcl-2. Ofthe
231 cases, 149 (64.5%) stained for bcl-2 protein. In 61 of the 149
(41%) bcl-2-positive tumours immunoreactive bcl-2 was detected
in 5-25% of the tumour cells. In 43 of 149 (29%) between 25%
and 50% ofthe tumour was stained and in 45 of 149 (30%) greater
than 50% of the tumour was immunoreactive. Figure 1 (A-C)
depicts representative immunohistochemical staining for control
colorectal tissue and bcl-2-negative and-positive tumours.
Association of bcl-2 expression with clinical or
histopathological features
Table 1 summarizes the analysis of the association between bcl-2
expression and histological parameters. There was no significant
association between bcl-2 expression and sex, performance status,
primary tumour site or stage at diagnosis. There was a marginal
association between low bcl-2 expression andpoorly differentiated
tumours (P=0.049). There was a significant association between
increased bcl-2 expression and low levels of plasma CEA
(P=0.013). However, log-rank survival analysis of bcl-2 staining,
stratifying by CEA level, demonstrated that bcl-2 was not an inde-
pendent factor (P=0.618).
Surgical group
In the group ofpatients with colorectal tumours of good prognosis
(n=96) the median follow-up was 39.5 months (6.5-99.5 months).
Thirteen patients relapsed with recurrent disease, six were bcl-2
positive and seven were bcl-2 negative (Table 2). The 5-year
event-free survival was 62.4% for bcl-2-negative tumours and
83.4% for bcl-2-positive tumours (P=0.150), whereas the 5-year
overall survival was 70.4% and 85% respectively (P=0.480).
Chemotherapy group
The median follow-up of the group with advanced disease that
received chemotherapy (n=135) was 19.7 months (4.4-41.4
months). Plasma CEA levels (P=0.002) and performance status
(P=0.017) were the only factors that influenced survival in this
group, whereas Dukes' stage at diagnosis had a marginal influence
on response to therapy (P=0.049) (Table 3). There was no difference
in bcl-2 expression in patients who had locally advanced disease at
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referral and those that had metastatic disease at referral (P=0.202).
Bcl-2 did not influence response to chemotherapy (P=0.211) nor
did it influence overall survival. The median failure-free survival
for bcl-2-negative tumours and for bcl-2-positive tumours was 5.1
and 5.7 months respectively (P=0.130) and their overall median
survival was 9 and 10.7 (P=0.150) months respectively.
DISCUSSION
In this study we wished to determine whether levels of bcl-2
expression were related to a number of histological parameters,
response to chemotherapy, rate of relapse or to overall survival in
patients that received either surgical or surgical plus chemothera-
peutic treatment for their colorectal tumours.
The staining pattern and distribution of bcl-2 were in broad
agreement with recent studies of bcl-2 expression in colorectal
tumours (Hague et al, 1994; Bosari et al, 1995; Ofner et al, 1995;
Sinicrope et al, 1995a,b; Baretton et al, 1996; Watson et al, 1996).
Increased bcl-2 expression was associated with low levels of
plasma CEA, a favourable marker for survival in this group of
patients (Webb et al, 1995). Several otherprognostically favourable
histological parameters have been reported to be associated with
increased bcl-2 expression; these include: smaller tumour size,
increased lymphocyte infiltration, low proliferation rate and diploid
tumours (as opposed to aneuploid) (Ofner et al, 1995; Sinicrope et
al, 1995a). In addition, two reports have reported an association
between low bcl-2 expression and poorly differentiated colorectal
tumours (Bosari et al, 1995; Watson et al, 1996). The degree of
differentiation has been reported to be a marker forprognosis, with
poorly differentiated tumours having a worse outcome (Chung et
al, 1982; Webb et al, 1995). We also detected a marginal associa-
tion of low bcl-2 expression with poorly differentiated tumours
(P=0.049). However, in this group ofpatients degree ofdifferentia-
tion did not influence overall survival or response to therapy.
In the surgically treated patient group bcl-2 did not influence the
number ofrelapses, although there was a slight increase in the time
to relapse and an increase in survival in patients with bcl-2-positive
tumours. This did not reach statistical significance, possibly
because only 13 of the 96 patients had recurrent disease. Other
studies have examined the association of bcl-2 with survival in
surgically treated colorectal cancer. Three studies concluded that
bcl-2 expression correlated with increased failure-free or overall
survival. In one of these, this was only apparent if the cut-off for
bcl-2 expression was greater than 50% of the tumour cells
(Sinicrope et al, 1995b) and in another bcl-2 was associated with
an increased disease-free survival, but after multivarient analysis
was not an independent prognostic factor (Baretton et al, 1996).
A fourth larger study could not demonstrate a significant associa-
tion with survival, although there was a trend towards increased
survival with high bcl-2 expression (Bosari et al, 1995).
A functional homologue of bcl-2 has been shown to have an
antiproliferative domain that is distinct from the domains required
for its antiapoptotic activity (Theodorakis et al, 1996). One
possible explanation for the reported association between bcl-2
and a favourable outcome could be the presence of a similar
antiproliferative domain in bcl-2. This domain would slow the rate
ofproliferation and hence increase survival in colorectal tumours.
Indeed, Sinicrope et al (1995a) have reported an association
between increased bcl-2 expression and decreased proliferation in
a group ofpatients where a high proliferation rate was an indepen-
dent marker of poor prognosis.
In this study bcl-2 expression did not influence response to
chemotherapy. Again the bcl-2-positive patients had a small
increase in survival, but this did not reach significance. To the best
ofourknowledge no other studies have reported on the relationship
between bcl-2 expression and response to chemotherapy in colo-
rectal adenocarcinomas. There are a number of explanations for
the lack of influence of bcl-2 on response to chemotherapy. Bcl-
2-negative colorectal tumour cells may lack mechanisms for
inducing apoptosis, for example the loss of cell death genes, such
as bax or p53, that are antagonized by bcl-2 (Oltvai et al, 1993;
Chiou et al, 1994). Alternatively, other bcl-2-related genes may be
expressed in bcl-2-negative tumours. Watson et al. (1996) used dual
labelling techniques to demonstrate reciprocity ofbcl-2 overexpres-
sion and stable overexpression of p53. This observation would
support the former idea. In addition, the response to 5-fluorouracil
will also be influenced by other factors, including the levels of
thymidylate synthetase (Johnston et al, 1995).
In conclusion, we hypothesized that bcl-2 expression may influ-
ence response to chemotherapy, but were unable to demonstrate
any effect of bcl-2 expression on response to chemotherapy in
patients,with advanced or metastatic disease. Nor were we able to
detect any influence ofbcl-2 expression on survival in eithergroup
ofpatients.
Baretton et al (1996) have suggested that the regulation ofapop-
tosis has a role in colorectal tumorigenesis. The number of genes
known to regulate this process is increasing. Until the molecular
mechanisms underlying this process are fully understood it will be
difficult, if not impossible, to assess the contribution of individual
genes such as bcl-2 in colorectal tumorigenesis and response to
chemotherapy. Further studies investigating the expression ofother
bcl-2-related genes that regulate apoptosis, the mechanisms regu-
lating bcl-2 expression in these tumours and the functional inter-
action of bcl-2 with other oncogenes involved in colorectal
tumorigenesis will be required before the role ofbcl-2 in colorectal
cancer is fully understood.
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